While it has been usual for biotech firms to receive between 5%and 10% of the revenues incurred in mutual projects, this number has grown in some cases to around 50% (Zanetti and Steiner 2001).Reepmeyer, G. (2006). Risk-sharing in the Pharmaceutical Industry: The Case of Out-licensing. 1st ed. [ebook] Physica-Verlag, p.55. Available at: https://books.google.com/books?id=qR7Tgu9G-QEC&dq=co-promotion&pg=PA55 [Accessed 3 Nov. 2015].
